Newsletter · · Ashutosh Agarwal

Biotech Thaws as the FDA's Reversal Train Now Has a Pattern - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 28, 2026

Biotech gene/cell, neuro and tools podcast pipeline for the week of June 21-28, 2026. A second rare-disease gene therapy joined the FDA's regulatory reversal, AbbVie's $10.9 billion Apogee takeout reopened the deal machine, and in-vivo editing drew fresh capital and a copycat fight.

Biotech Pipeline: Gene/Cell, Neuro & Tools

Week of June 28, 2026: Biotech Thaws as the FDA's Reversal Train Now Has a Pattern

A week ago, the FDA's about-face on a Huntington's gene therapy looked like a one-off, a single drug clearing a single gate. This week it stopped looking like an exception and started looking like a regime. A second rare-disease gene therapy got the same treatment, two more names were name-checked as having quietly turned positive, and the dealmakers came back to the table in size. Put the regulatory thaw next to a $10.9 billion takeout and a chart guy on CNBC calling the bottom, and the read for the first time in a long while is simple: the freeze is breaking.

TL;DR

  • The FDA's "reversal train" added a second gene-therapy car. Regenxbio's Hunter syndrome program, rejected in February, was told its original data is now sufficient for an accelerated-approval filing with no additional studies, joining uniQure's Huntington's reversal. Both target Q3 submissions, and the desk is openly asking whether this sticks past an acting commissioner. (BioSpace, Jun 24)
  • M&A is speeding up and the tape is bottoming. AbbVie's $10.9B grab of Apogee drove its best day since 2020, and Carter Worth called the XBI a textbook "bearish to bullish reversal," biotech still down 18% from its 2021 peak while the S&P is up ~90%. (CNBC Fast Money, Jun 22)
  • In-vivo editing keeps drawing capital, and a copycat fight. A China-sourced in-vivo editing asset for AATD got reverse-merged into a ~$230M vehicle, sparking a public "is this just a Beam clone?" spat between two of the field's loudest voices. (Biotech Hangout, Jun 26)

What's new

The FDA reversal is now a pattern, not an anecdote. On the June 24 BioSpace podcast, the editors framed it bluntly: "Regenex Bio and Unicure are the latest rare disease biotechs to climb aboard the FDA's new regulatory reversal train," and this time the train is "going in a different direction… in the company's favors." Regenxbio's Hunter syndrome gene therapy had been rejected in February over eligibility criteria and external controls; after an appeal, "the FDA is now saying the original data is sufficient for an application and under-accelerated approval path and that no additional studies are required," with a Q3 filing planned. That sits on top of uniQure's Huntington's reversal (also Q3), where the "new, new FDA agreed that these three-year data… could support accelerated approval." And the editors flagged it's broader still: "Replimune and Disc Medicine have also reported positive regulatory news since Marty McCary's departure in early May." (BioSpace)

The deal machine restarted, and the chart agrees. On the June 22 CNBC Fast Money, the desk led with AbbVie: shares "up 8%," the company "going to buy a company called Apogee Therapeutics for about $10.9 billion… its best day since 2020," and the verdict that "the biotech M&A race is starting to speed up." Carter Braxton Worth turned that into a sector call: biotech "peaked in February of 2021… Since that peak, the S&P is up 90%, 92%… Biotech is down 18%. But it's bottoming. That relative performance chart has all the elements of a bearish to bullish reversal." Guy Adami's coda: "there's going to be more M&A in the space as we get to the second half of the year. So you want to be long biotech." (CNBC Fast Money)

In-vivo editing got another well-funded entrant, and an immediate "me-too" challenge. On the June 26 Biotech Hangout, host Josh walked through Sarafa: an "investigational in vivo-based editing therapy for alpha-1 antitrypsin deficiency," built on technology from China-based Yoltec, reverse-merged into Boundless Bio with "$138 million in a Series A, plus $92 million to come and close a deal, co-led by RA Capital and RTW," funding the program "to the second half of 2029, to finish phase two, and start phase three." It promptly drew fire: Arch's Bob Nelson suggested Sarafa "was kind of just a copycat of Beam," with Peter Kolchinsky countering "there's some data to still come out… before we just call it a Me Too." (Biotech Hangout)

A bankruptcy is becoming a gene-therapy fire sale, with big pharma bidding. Both BioSpace and the Hangout flagged Sangamo's bankruptcy filing, with Eli Lilly moving to "pick up three of their platforms plus an early stage AAB gene therapy program" and Astellas bidding on its Fabry disease therapy (a rolling BLA already in progress). Both are stalking-horse bidders in a "court supervised auction." It's a reminder that even as the gate reopens, the prior funding winter is still claiming platform companies, and the strategics are shopping the wreckage. (BioSpace; Biotech Hangout)

The debate

Is the FDA's constructiveness a regime change or just a caretaker's mood? The bull case is on the tape and getting harder to wave away: two gene therapies reversed to accelerated approval in a single week, two more names turning positive, and a stated push to reshore early-stage trials. But the same BioSpace desk steel-manned the bear case itself, the industry is getting "whiplash," with one set of guidance in 2024, "completely something else last year," and a reversal now, leaving the open question of whether this is durable "or is this just under the FDA and in its caretaker mode under Kyle Diamantis, the acting commissioner." The candor at BIO 2026 cut both ways: the mood was "a more upbeat optimistic vibe than we've seen in years past," yet a panel of former FDA hands called the surprise release of complete response letters "forced transparency" that "blindsided the industry" and, per former agency lawyers, "wasn't even legal." The honest read: the door is open, but it's being held open by an acting commissioner, and no one this week claimed the new posture is locked in. (BioSpace)

Read-throughs & names in play

  • uniQure (QURE) / Regenxbio (RGNX). The two cleanest proxies for the regime change, both with Q3 filings on accelerated approval and confirmatory-trial overhangs. Bull: disease-modifying rare-disease assets clearing a gate that was shut a quarter ago. Bear: thin packages riding a regulatory mood that may not survive a permanent commissioner. (BioSpace)
  • AbbVie (ABBV) / biotech beta (XBI). Apogee gives the M&A thesis a marquee print; the technical call says the whole complex is catching up to a market that left it behind. Bull: more take-outs into 2H and a five-year base breaking. Bear: it's still a "catch-up" trade, not leadership. (CNBC Fast Money)
  • Eli Lilly (LLY). Quietly everywhere this week: stalking-horse bidder on Sangamo's gene-therapy platforms, and Evaluate projecting its tirzepatide brands (Mounjaro/Zepbound) past "$70 billion" by 2032 with the new oral, Famdeo, adding "$25 billion plus." The gene-therapy bid is the tell that big pharma wants in-house delivery platforms cheap. (BioSpace; Biotech Hangout)
  • Beam (BEAM). Pulled into the spotlight not by its own data but as the benchmark in the Sarafa "copycat" fight, a reminder that in-vivo editing is now crowded enough that incumbents are policing the perimeter. (Biotech Hangout)
  • Pfizer (PFE). Its antibody-drug-conjugate sigvotatug vedodin "failed that phase three trial" in pretreated lung cancer, but management is leaning on a post-hoc second-line signal and a larger first-line study with Keytruda due next year. Tim Seymour stayed long, arguing "the story has been somewhat de-risked." (CNBC Fast Money)
  • Thermo Fisher (TMO), and the CGT picks-and-shovels. Two appearances this week, both qualitative: cell-and-gene-therapy manufacturing flagged as the hottest university research vein "because… we got more and more approvals for cell therapies," and a candid take that AI in the lab "won't deliver until your data is connected." No book-to-bill, but the demand narrative for CGT tooling is intact. (AUTM on the Air, Jun 24; Smart Biotech Scientist, Jun 23)
  • The CAR-T access problem (read-through for autologous cell therapy). A Yescarta launch post-mortem laid out why autologous CAR-T stays bottlenecked: hospitals "only reimburse the cost of Yescarta," community centers lack infrastructure, and every sponsor builds "their own system." The unlock, per the operator who ran it: when CAR-T "gets shelf-stable and not individualized." Bullish for allogeneic and in-vivo approaches by contrast. (Citeline Podcasts, Jun 22)

What changed

Last week the FDA reversal was one drug and a hopeful inference; this week it's a pattern with a name, the "reversal train," and a second gene therapy (Regenxbio) on board, plus Replimune and Disc Medicine cited as fellow beneficiaries. The other delta is risk appetite: the M&A "race is starting to speed up," AbbVie put a $10.9B exclamation point on it, and the sell-side technicals flipped from "completely ignored" to "bearish to bullish reversal." On the China debate, the framing sharpened, one desk netted out that 2025's headline "$136 billion of out-licensing deals from China" is really only "$5.6 billion in upfronts," set against a single $10.9B US acquisition, as evidence value creation "is accruing… [to] the U.S. market." (BioSpace; CNBC Fast Money; Biotech Hangout)

What's quiet

The anti-amyloid launch tape stayed light. The only neuro coverage was a clinician's candid real-world view, that anti-amyloid drugs are the "only" way to clear amyloid yet deliver benefit closer to "30% slowing" than the "100%" patients want, and that direct-to-consumer p-tau217 blood tests aren't yet trustworthy ("I just don't trust the accuracy yet"), with no Leqembi or Kisunla patient-start metrics, nothing on SubQ, ARIA, or CMS coverage from Biogen/Eisai or Lilly. On tools, no podcast gave voice to Danaher, Agilent, Revvity, Sartorius, Repligen, Bruker, Waters or Illumina, and there was no fresh single-use book-to-bill, destock-to-restock, or NGS-pricing tape. And no company-specific data from CRISPR Therapeutics, Intellia, Verve, Vertex/Casgevy, Editas or Prime, nor any in-vivo ATTR/ANGPTL3/PCSK9 readout. (Brain Talk, Jun 23)